Research Article

Vitronectin, a Novel Urinary Proteomic Biomarker, Promotes Cell Pyroptosis in Juvenile Systemic Lupus Erythematosus

Song Zhang,1,2 Wenxu Pan,1,3 Hongli Wang,3 Cheng Zhi,4 Yanhao Lin,5 Ping Wu,2 Qi Ren,2 Ping Wei,2 Rui Chen,6 Feng Li,2 Ying Xie,2 Chun Kwok Wong,7,8 Hong Tang,9 Zhe Cai,2,8,10 Wanfu Xu,3,10 and Huasong Zeng1,2

1The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children’s Medical Center, Guangzhou 510623, China
3Department of Gastroenterology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, China
4Department of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
5Heyuan Heping County Maternal and Child Health Hospital, Heyuan, Guangdong 517200, China
6Shenzhen Bionavi Life Sciences Co., Ltd., Shenzhen, Guangdong 518118, China
7Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong 999077, China
8Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China
9Institute Pasteur of Shanghai, Chinese Academy of Science, Shanghai 200031, China
10Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, China

Correspondence should be addressed to Zhe Cai; caifranklin@163.com, Wanfu Xu; xushi123@gmail.com, and Huasong Zeng; zenghuasong@gwcmc.org

Received 28 August 2021; Revised 9 February 2022; Accepted 21 March 2022; Published 13 April 2022

Academic Editor: Helen C. Steel

Copyright © 2022 Song Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Identifying new markers of juvenile systemic lupus erythematosus (JSLE) is critical event to predict patient stratification and prognosis. The aim of the present study is to analyze alteration of urinary protein expression and screen potential valuable biomarkers in juvenile systemic lupus erythematosus (JSLE). Methods. The urine was collected from the patients with or without JSLE and detected by mass spectrometry to analyze proteomic changes. ELISA was used to verify the Vitronectin (VTN) changes in a new set of patients. The clinical correlation was performed to analyze between VTN and clinical pathological parameters. WB and ELISA were used to analyze VTN-mediated cell pyroptosis. Results. Herein, we have identified a group of 105 differentially expressed proteins with ≥1.3-fold upregulation or ≤0.77-fold downregulation in JSLE patients. These proteins were involved in several important biological processes, including acute phase inflammatory responses, complement activation, hemostasis, and immune system regulation through Gene Ontology and functional enrichment analysis. Interestingly, urinary ephrin type-A receptor 4 (EPHA4) and VTN were significantly reduced in both inactive and active JSLE patients, and VTN treatment in THP-1 derived macrophages led to a significant increased cell pyroptosis by activation of Nod-like receptor family protein 3 (NLRP3) inflammasomes, resulting in caspase-1 activation, cleaved gasdermin D (GSDMD), and IL-18 secretion. Most importantly, the urinary VTN was also linearly correlated with clinical characteristics of JSLE, implying that VTN could be a specific diagnostic biomarker to distinguish inactive and active JSLE. Conclusion. This study provided a novel role of VTN in pyroptosis in JSLE through the urinary proteomic profile for JSLE, which could be a nonintrusive monitoring strategy in clinical diagnosis.
1. Introduction

Systemic lupus erythematosus (SLE), an autoimmune disease with inflammation, affects multiple organ systems characterized by excessive production of antinuclear antibodies and high morbidity and low quality of life [1–3]. The precise pathophysiological mechanism of SLE is largely unknown. One of the most important mechanisms involved in SLE is alteration of immune reactions, which involved autoantibodies that target the patient’s own tissues and subsequently lead to the inflammation [4]. Despite tremendous basic and clinical research progress regarding treatment [5], various cytokines and chemokines have emerged as the potential biomarkers of SLE disease activity [6]. However, due to the complexity of this disease, the clinical usefulness of these potential biomarkers in assessing disease in SLE is not well established, especially through noninvasive and easy collected urine samples to diagnose renal activity of SLE.

The changes in humoral metabolomics, including serum, plasma, urine, and sputum, can provide abundant information on the physiological and pathological states of individuals and useful clinical parameters. Consequently, to understand the enormous potential in terms of revealing disease conditions will also bring the promise of a revolution in disease diagnosis and therapeutic monitoring [7–10]. In a previous study, 23 differential metabolites and 5 perturbed pathways including aminoacyl-tRNA biosynthesis, thiamine metabolism, nitrogen metabolism, tryptophan metabolism, and cyanoalanine acid metabolism were identified between SLE patients and healthy controls [1]. Also, the studies exhibited that immunoglobulin-binding protein [7], urinary vitamin D-binding protein, and S100 calcium-binding protein (S100) were the potential biomarkers in patients with lupus nephritis [11, 12]. With significant advances in proteomic technologies, the comprehensive profiling of protein expression in biofluids from patients with a given disease prompts a deep exploration of disease and its underlying mechanisms. In an attempt to reach greater understanding of the pathogenesis, based on advantage of proteomic technologies, we tried to seek potential information in urine to differentiate inactive juvenile SLE (JSLE) patients from active ones and healthy donors.

Vitronectin (VTN), a multifunctional glycoprotein, has been demonstrated to be enriched in the serum, extracellular matrix, and platelets [13] and regulated cell adhesion, coagulation, fibrinolysis, complement activation, and apoptosis by interacting with integrin αvβ3, plasminogen activator Inhibitor-1 (PAI-1), and urokinase plasminogen activator (uPAR) [14, 15]. Also, it has been reported that VTN was associated with inflammation in several biological processes, such as acute lung injury, burns, and sepsis, which were involved in the neutrophil and autoreactive T and B lymphocyte activation and tissue injury [16–19]. In addition to VTN, ephrin type-A receptor 4 (EPHA4), belonging to the ephrin receptor subfamily of the protein-tyrosine kinase family, has been implicated in mediating developmental events and associated with the development of SLE, particularly in the central nervous system lupus erythematosus (CNS-SLE) [20, 21]. What is more, ephrin-A1-EphA4 signaling has reported to negatively regulate with myelination in the central nerve system [20]. Up to now, some proteomic changes of urine have been described in SLE patients. However, the proteomics of urinary specific biomarkers that distinguished the inactive JSLE and active JSLE remained to be identified.

In this study, we further showed that the VTN and EPHA4, decreased in JSLE by urinary protein profiling, could be considered the novel biomarkers associated with the autoimmune inflammation among healthy donors and inactive and active JSLE patients. Therefore, the alteration of VTN and EPHA4 proteins could be a potential strategy to develop innovative therapeutic approaches.

2. Materials and Methods

2.1. Patients and Study Design. A total of 9 healthy controls (group 1/G1) and 19 patients diagnosed with SLE (group 2/G2: 9 inactive JSLE patients; group 3/G3: 10 active JSLE patients) were recruited in Guangzhou Women and Children’s Medical Center. The written informed consent was obtained from all subjects according to the Declaration of Helsinki. This clinical ethical was approved by the Ethics Committee of Guangzhoun Women and Children’s Medical Center. The clean morning urine samples were collected and centrifuged at 3000 g, at 4°C for 15 min. The supernatant was stored at -80°C for further proteomics analysis.

2.2. Disease Activity Assessment. Disease activity assessment was performed using the modified SLE Disease Activity Index 2000 (SLEDAI-2K) described in the previous study [22]. The modified SLEDAI-2K excludes 2 immunological items (the complement levels and anti-double-stranded DNA/dsDNA) from the original SLEDAI-2K, while maintaining the 16 clinical manifestations and 4 laboratory tests (white blood cell count, platelet count, urinalysis, and 24-hour proteinuria). Since the British Isles Lupus Assessment Group 2004 (BILAG-2004) index provided detailed assessments including severity for affected organs and system manifestations [23], we have modified the total BILAG-2004 index based on the scorings of A = 12, B = 8, C = 1, and D/E = 0. The inactive disease of JSLE patients was defined as above modified BILAG-2004 index C/D/E or modified SLEDAI-2K scores < 5. The active JSLE patients were determined by modified BILAG-2004 index A/B or modified SLEDAI-2K scores ≥ 5. Several clinical manifestations of healthy controls were also demonstrated in the comparison to JSLE patients. Therefore, the correlation between the differentiated protein levels and the severity of certain organ/system manifestations of JSLE patients were also determined.

2.3. Sample Preparation, Mass Spectrometry (MS), and MS Interpretation. All samples were prepared for proteomics assay with the following preparations. Protein concentration in the urine was determined using a BCA kit (Beyotime, P0009) according to the manufacturer’s instructions. For digestion, dithiothreitol was used to concentrate the total protein solution for 30 min at 56°C, and then, alkylation of protein with 11 mmol/L iodoacetamide was performed for 15 min at room temperature in the dark. After trypsin digestion, the peptides were combined and dried and then subjected to an nitrogen solubility index source followed by tandem mass spectrometry.
(MS/MS) in Q-Exactive (Thermo Fisher Scientific, San Jose, CA, USA) coupled online to an ultraperformance liquid chromatography system. The resulting MS/MS data were processed using MaxQuant with the integrated Andromeda search engine (v.1.5.2.8). Gene Ontology (GO) was a major bioinformatics initiative to unify the representation of the gene and gene product attributes across all species. The GO annotation proteome was derived from the UniProt-GOA database (http://www.ebi.ac.uk/GOA). The Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to connect known information on molecular interaction networks. These pathways were classified into hierarchical categories according to the KEGG website.

2.4. Protein-Protein Interaction (PPI) Network Construction and Module Analysis. The Search Tool for the Retrieval of Interacting Genes (STRING) online database (https://string-db.org/cgi/input.pl) tool was employed to construct the PPI network.

2.5. Cell Culture and Treatment. THP-1 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the manufacturer’s recommendations. Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco (Thermo Fisher Scientific, USA). The cells were treated with PMA (100 nM, P6741, Solarbio, Beijing, China) for 72 hours and induced into macrophages. For cell treatment, VTN (P00082, Solarbio, Beijing, China) was used to treat THP-1-derived macrophages at 4 μM. Other reagents used in this study were purchased from Sigma.

2.6. Western Blotting. As described in our previous study [24], the whole cell lysate was harvested and subjected to SDS-PAGE and transferred into the nitrocellulose transfer membrane. After incubation with 5% (w/v) milk in PBS/0.05% (v/v) Tween-20 for 1 hour, the membrane was incubated with indicated antibodies overnight at 4°C, subsequently followed by incubation with a horseradish peroxidase secondary antibody (Jackson ImmunoResearch) for 1 hour at room temperature. Proteins were detected using an enhanced chemiluminescence (PerkinElmer). The antibodies used in this study were from Abcam: NLRP3 (ab263899, 1:2000 for WB), IL-1β (ab254360, 1:1000 for WB), caspase-1 (ab179715, 1:1000 for WB), ASC (AB283684,1:2000 for WB), GSMD (ab219800, 1:2000 for WB), NF-κB (ab207297, 1:2000 for WB), phospho-NF-κB (ab239882, 1:2000 for WB), β-actin (ab8226, 1:4000 for WB), and α-tubulin (ab7291, 1:5000 for WB).

2.7. Real-Time PCR. As described in our previous study [25], the total RNA was extracted according to the instruction. The All-in-One First-Strand cDNA Synthesis Kit and All-in-One qPCR Mix were used to perform reverse transcription and quantitative PCR (qPCR) according to the manufacturer’s protocol. The primers used in this study are as follows: IL-1β: forward: 5′-ATGATGGGCTTATTACAGTGCAA-3′ and reverse: 5′-TCCGGGGTGCATTATCTCTAC-3′; GSMD: forward: 5′-GTTGTTGTAACCTGCTATCAAGG-3′ and reverse: 5′-CATGGGTCATGTAAGTGGAAAG-3′; NLRP3: forward: 5′-GATCTGCTGGAGATCGGAC-3′ and reverse: 5′-CTGTGATTACCTGAACCCAC-3′; ASC: forward: 5′-TGGATGCTCTGTACGGGAAG-3′ and reverse: 5′-CCAGCCTGGTGGAATCTGAA-3′; caspase-1: forward: 5′-CTATATTATGCAAGACTCTCAAGGA-3′; and UBC: forward: 5′-ATTTGGTTCGCGGTTCCTTG-3′ and reverse: 5′-TGCCCTTGACATTCTCGATGGT-3′.

2.8. ELISA. IL-1β (ab229384) and IL-18 (ab215539) in culture supernatants were measured and quantitated for the indicated group by ELISA according to the manufacturer’s instructions, respectively.

2.9. Relative Cell Death Assays. LDH assay kit (Abcam, ab102526) was used to analyze LDH in supernatants from THP-1-derived macrophages treated in the experiment according to the manufacturer’s instructions. Relative cell death was determined as described in Zhou et al.’s study [26].

2.10. Statistical Analysis. Statistical analysis of in vivo data was described in the section of each assay. Results were expressed as mean ± standard deviation (SD) for normally distributed data. Mann-Whitney U test was tested for the continuous variables. Comparison of different groups was made with Kruskal-Wallis analysis of variance (ANOVA), followed by Dunn’s posttest for comparing the differences and calculating a probability (p) value for each pair of comparison. All hypotheses were two-tailed, and p values less than 0.05 were considered significant. Spearman’s rank correlation test was used to assess the lineal correlations among the urinary VTN expression with clinical parameters of JSLE patients. r is the correlation coefficient. The t-test was performed in qPCR and ELISA analysis. Data were analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA).

3. Results

3.1. Patients and Clinical Characteristics. As shown in Table 1, a total of 28 early morning urine samples were collected from 9 healthy controls, 9 patients with inactive JSLE, and 10 patients with active JSLE. We found that creatinine level in healthy control is lower than inactive JSLE patients (22.87 ± 4.37 versus 61.13 ± 15.99, p < 0.05); the higher mean ratio of aspartate amino transferase (AST)/alanine amino transferase (ALT) was observed in inactive (1.47 ± 0.62 versus 2.54 ± 0.79, p < 0.01) and active (1.36 ± 0.72 versus 2.54 ± 0.79, p < 0.01)JSLE patients compared with healthy controls, respectively, while lower hemoglobin (HB) levels in active JSLE patients (96.78 ± 25.92 g/L) were found compared to those in healthy controls (96.78 ± 25.92 versus 126.10 ± 31.90) and inactive JSLE patients (96.78 ± 25.92 versus 116.00 ± 21.33), respectively.
versus 0 while erythrocyte sedimentation rate (ESR) (fold downregulation) proteins were quantified in active JSLE patients; through liquid chromatography- (LC-) mass spectrometry (MS). Bioinformatics analysis of 16 downregulated proteins (≤0.77-fold downregulation) and 9 upregulated proteins (≥1.3-fold upregulation) was obtained between JSLE patients (G2+G3) and healthy controls (Figures 1(a) and 1(b)). Further results showed that a total of 3 increased (≥1.3-fold upregulation) and 34 decreased (≤0.77-fold downregulation) proteins were quantified between G2 and G1 (Figure 1(c)), while 21 increased (≥1.3-fold upregulation) and 16 decreased (≤0.77 downregulation) proteins were observed in a comparison between G3 and G1 (Figure 1(d)). Interestingly, compared to the G2, only 2 decreased proteins and 47 increased proteins were found in the urine of active JSLE patients (Figure 1(e)).

Based on these findings, to further explore the specific differentially expressed genes (DEGs) among three groups, we overlapped the downregulated proteins that reflected gene expressions, and we achieved two downregulated proteins in JSLE patients compared with healthy controls (VTN and EPHA4, shown in Figure 2(a)), whereas none was obtained by overlapping the upregulated proteins (Figure 2(b)). All these DEGs are listed in Figure 2(c).

### 3.2. Proliferation of the Proteome in the Urine of JSLE Patients

Proteomics analysis was then performed on the urine samples. As shown in Figure 1(a), heatmap results showed that 105 different proteins have been identified among groups (group 1/G1: healthy controls; group 2/G2: inactive JSLE patients; and group3/G3: active JSLE patients) through liquid chromatography- mass spectrometry (MS). Bioinformatics analysis of 16 downregulated proteins (≤0.77-fold downregulation) and 9 upregulated proteins (≥1.3-fold upregulation) was obtained between JSLE patients (G2+G3) and healthy controls (Figures 1(a) and 1(b)). Further results showed that a total of 3 increased (≥1.3-fold upregulation) and 34 decreased (≤0.77-fold downregulation) proteins were quantified between G2 and G1 (Figure 1(c)), while 21 increased (≥1.3-fold upregulation) and 16 decreased (≤0.77 downregulation) proteins were observed in a comparison between G3 and G1 (Figure 1(d)). Interestingly, compared to the G2, only 2 decreased proteins and 47 increased proteins were found in the urine of active JSLE patients (Figure 1(e)).

### 3.3. Functional Enrichment Analysis

To further analyze these DEGs involved in the possible biological function, the enrichment analysis was performed by the GO and KEGG terms, including molecular function, cellular component, and biological process that were significantly enriched to indicate the nature of the differentially expressed proteins in urine between JSLE patients and healthy controls using the Database for Annotation, Visualization and Integrated Discovery online tool.

As for the DEGs in analysis of inactive JSLE patients and healthy controls, multiple enriched GO terms and KEGG pathways were demonstrated. The top 20 enriched GO terms and KEGG pathways were selected and are shown in Figure 3.

### Table 1: Demography of clinical characteristics for JSLE patients and healthy controls (mean ± SD).

| Parameters       | Healthy controls (n = 9) | Inactive JSLE (n = 9) | Active JSLE (n = 10) |
|------------------|--------------------------|-----------------------|----------------------|
| Age              | 3.38 ± 1.02              | 9.80 ± 1.00∗          | 10.80 ± 0.97∗        |
| Gender (M/F)     | 2/7                      | 0/9                   | 0/10                 |
| Disease duration (year) | NA.                     | 1.44 ± 0.69           | 2.03 ± 1.65          |
| SLEDAI           | NA.                      | 4.11 ± 4.08           | 11.50 ± 7.29         |
| SLICC            | NA.                      | 1.56 ± 1.59           | 3.60 ± 2.59          |
| Hematuria        | 0/9                      | 1/9                   | 5/10                 |
| Proteinuria      | 0/9                      | 0.75 ± 0.13           | 0.38 ± 0.39          |
| C3 (g/L)         | NA.                      | 0.14 ± 0.04           | 0.06 ± 0.05          |
| C4 (g/L)         | NA.                      | 16.71 ± 14.85         | 417.6 ± 201.8        |
| ANA (g/L)        | NA.                      | 14.52 ± 12.27         | 443.1 ± 309.7        |
| dsDNA (g/L)      | NA.                      | 29.11 ± 22.86         | 6.50 ± 6.76          |
| Creatinine (μmol/L) | 22.87 ± 4.37            | 61.13 ± 15.99∗        | 33.30 ± 1.90         |
| Uric acid (μmol/L) | 293.80 ± 107.20         | 399.40 ± 90.87        | 318.70 ± 85.48       |
| AST/ALT ratio    | 2.54 ± 0.79              | 1.47 ± 0.62∗          | 1.36 ± 0.72∗         |
| CRP (mg/L)       | 8.94 ± 7.64              | 5.12 ± 7.18           | 2.13 ± 3.29          |
| WBC (10⁹/L)      | 6.70 ± 4.29              | 7.73 ± 2.19           | 7.46 ± 1.78          |
| HB (g/L)         | 126.10 ± 31.90           | 116.00 ± 21.33        | 96.78 ± 25.92∗       |
| PLT (g/L)        | 238.20 ± 99.58           | 246.70 ± 108.70       | 260.80 ± 129.20      |

The statistically significant differences were shown between JSLE patients and healthy controls (∗p < 0.05, **p < 0.01), as well as the significant differences between the active and inactive JSLE patients (∗∗p < 0.01, and ***p < 0.001). There are no statistically significant differences in the parameters of gender, disease duration, SLICC, proteinuria, uric acid, CRP, WBC, and PLT among groups.
Figure 1: Continued.

Mediators of Inflammation
Figure 1: Continued.
Figure 1: Profile of urinary proteins. (a) Heatmap shows the differentially expressed genes (DEGs) reflected by differentially expressed matching proteins in the indicated groups (group 1/G1: healthy controls, group 2/G2: inactive JSLE patients, and group 3/G3: active JSLE patients). Red and green colors indicate higher and lower expression, respectively. (b–e) Volcano dot plot presents the mass spectrometry data of proteome as -log10 (p value) plotted against the log2 (fold change/FC). The -log10 (p value) and log2 (FC) analysis thresholds are indicated by dotted lines (≥1.3-fold upregulation or ≤0.77-fold downregulation, p < 0.05). Green dots represent the downregulated proteins, while red dots represent the upregulated proteins and gray dots represent no significant difference in proteins. The symbol of differentially expressed proteins labeled with relevant color is listed beside each graph.
Figure 3(b) showed that the main enrich GO terms were majorly associated with cell adhesion, biological adhesion, peptidyl-tyrosine phosphorylation, peptidyl-tyrosine modification, and cell-cell adhesion via plasma-membrane adhesion molecules. When compared with healthy controls and inactive JSLE patients, the differentially enriched KEGG pathways are listed in Figure 3(a). Also, the involvement of salivary secretion, the PI3K-Akt signaling pathway and human papillomavirus infection as well as biological function was related to posttranslational protein modification, protein modification, cell adhesion, and cellular protein modification process in the comparison of active JSLE patients and healthy controls (Figures 3(c) and 3(d)). In addition, from the comparison results of inactive and active JSLE patients, we also found DEGs participating in multiple biological pathways, such as necroptosis, focal adhesion, and PI3K-Akt signaling that were involved in the regulation of mitotic nuclear division and nuclear division (Figures 3(e) and 3(f)).

### 3.4. The Protein-Protein Interaction Analysis of Different Genes

To clearly understand the interaction of downregulated DEGs, the PPI network of these DEGs was generated to identify the key genes and their interactions in JSLE utilizing the STRING online database. As shown in Figure 4, these results showed that VTN is formed as a core molecule of the PPI network among three groups, at least interacting with other genes in the interactomic networks, including collagen type XVIII alpha 1 (COL18A1), fibrin 5 (FBLN5), aggrecan (ACAN), junctional adhesion molecule-A/F11 receptor (F11R), and prion protein (PRNP). As for the active and inactive JSLE,
Figure 3: Continued.
### Table 1: Significantly Enriched Pathways

| Pathway                                              | Rich Factor |
|------------------------------------------------------|-------------|
| Salivary secretion                                   | 0.545       |
| Ribosome                                             |             |
| PI3K-Akt signaling pathway                           |             |
| Osteoclast differentiation                            |             |
| Non-small cell lung cancer                            |             |
| Neuroreceptor-ligand interaction                      |             |
| JAK-STAT signaling pathway                           | 0.540       |
| Human papillomavirus infection                        |             |
| Focal adhesion                                       |             |
| ErbB signaling pathway                                |             |
| Endometrial cancer                                    |             |
| Cytokine-cytokine receptor interaction                | 0.535       |
| Colorectal cancer                                     |             |
| Sphingolipid signaling pathway                        |             |
| Ras signaling pathway                                 |             |
| Rap1 signaling pathway                                |             |
| Pancreatic cancer                                     |             |
| Inflammatory mediator regulation of TRP channels      |             |
| Complement and coagulation cascades                   | 0.530       |

### Figure 3: Continued.

- **(c)**: Bar chart showing protein number and -log10(p-adjust) for Group 3 vs Group 1.
- **(d)**: Bar chart showing protein number and -log10(p-adjust) for Group 3 vs Group 1.
Group 3 vs Group 2

0.2 0.3 0.4 0.5
Rich factor

-log10(p-adjust)

Pathway
- Necroptosis
- Focal adhesion
- PI3K-Akt signaling pathway
- Cell adhesion molecules (CAMs)
- Human papillomavirus infection
- Endocytosis
- ECM-receptor interaction
- Protein digestion and absorption
- Taurine and hypotaurine metabolism
- Progesterone-mediated oocyte maturation
- Mannose type O-glycan biosynthesis
- Calcium signaling pathway
- Th17 cell differentiation
- Small cell lung cancer
- Serotonergic synapse
- Prostate cancer
- N-Glycan biosynthesis
- MicroRNAs in cancer
- Lysine degradation
- Choline metabolism in cancer

Figure 3: Continued.
VTN, COL18A1, and ACAN were also significant hub genes in the interatomic networks.

3.5. Correlation between Urine VTN Levels and Lupus Clinical Parameters. In this study, upon the quantitative results, we tried to seek the clinical values for a detection of urinary VTN in JSLE patients. We found that VTN was negatively associated with serum dsDNA (inactive JSLE: \( r = -0.8313, p < 0.05 \), Figure 6(b)) in the peripheral blood mononuclear cell (PBMC), as well as positively associated with \%CD16\(^+\)CD56\(^+\) NK cells (\( r = 0.6724, p < 0.05 \), Figure 6(c)) in the whole blood of inactive JSLE. The similar relationship was obtained in an analysis for the correlations of VTN with the ratio of \%CD3\(^+\) T cells/%CD45\(^+\) lymphocytes (\( r = 0.6257, p < 0.05 \), Figure 6(d)), %CD3\(^+\)CD4\(^-\)CD8\(^-\) T cells (Th) (\( r = -0.8716, p < 0.01 \), Figure 6(e)), and %CD3\(^+\)CD8\(^+\) suppressor T cells (Ts) (\( r = 0.8385, p < 0.01 \), Figure 6(f)), the ratio of %CD4\(^+\) Th/%CD8\(^+\) Ts (\( r = -0.6881, p < 0.05 \), Figure 6(g)) and %CD16\(^+\)CD56\(^+\) NK cells (\( r = -0.7663, p < 0.01 \), Figure 6(h)), and absolute number of NK cells (\( r = -0.6813, p < 0.01 \), Figure 6(i)) in PBMC of active JSLE. Moreover, no significant associations were observed between VTN and other index (data not shown).

3.6. Correlation between Urine VTN Levels and Different Lymphocyte Subsets. SLE is characterized by the loss of tolerance to self-antigens, downstream activation, and expansion of autoreactive T and B lymphocytes [19]. In this study, upon the quantitative results, we found that urine VTN level was negatively associated with %CD19\(^+\) B cells (\( r = -0.8978, p < 0.01 \), Figure 6(a)) and %CD3\(^+\)CD4\(^+\)CD8\(^-\) T cells (\( r = -0.8313, p < 0.05 \), Figure 6(b)) in the peripheral blood mononuclear cell (PBMC), as well as positively associated with %CD16\(^+\)CD56\(^+\) NK cells (\( r = 0.6724, p < 0.05 \), Figure 6(c)) in the whole blood of inactive JSLE. The similar relationship was obtained in an analysis for the correlations of VTN with the ratio of %CD3\(^+\) T cells/%CD45\(^+\) lymphocytes (\( r = 0.6257, p < 0.05 \), Figure 6(d)), %CD3\(^+\)CD4\(^-\)CD8\(^-\) T cells (Th) (\( r = -0.8716, p < 0.01 \), Figure 6(e)), and %CD3\(^+\)CD8\(^+\) suppressor T cells (Ts) (\( r = 0.8385, p < 0.01 \), Figure 6(f)), the ratio of %CD4\(^+\) Th/%CD8\(^+\) Ts (\( r = -0.6881, p < 0.05 \), Figure 6(g)) and %CD16\(^+\)CD56\(^+\) NK cells (\( r = -0.7663, p < 0.01 \), Figure 6(h)), and absolute number of NK cells (\( r = -0.6813, p < 0.01 \), Figure 6(i)) in PBMC of active JSLE. Moreover, no significant associations were observed between VTN and other index (data not shown).

3.7. VTN Induced Cell Pyroptosis in THP-1-Derived Macrophages. To further explore the possible function of VTN in SLE, the THP-1-derived macrophages were used in the in vitro model and treated with or without VTN to detect cell pyroptosis change. As shown in Figure 7(a), morphologically, a larger number of dead cells were observed in THP-1-derived macrophages treated with VTN compared with the control.
Group 2 vs Group 1

(a)

Group 3 vs Group 1

(b)

Figure 4: Continued.
Group 3 vs Group 2

B3GNT1
ACAN
TNXB
DDR1
COL2A1
CSPG4
VTN
FBLN5
SERPING1
COL18A1
COL4A2
PDGFRB
CD7
NCAM1
PVRL1
CEACAM8
C1RL
PDCD6IP
CHMP4B
CHMP1B
CHMP1A
CDH5
CDHR5
LYPD3
NEGR1
GPRC5B
MFI2
APP
XPNPEP2
CHMP2B
(c)

Group 2 vs Group 1

Viral myocarditis
5%
Tryptophan metabolism
5%
TNF signaling pathway
5%
Rheumatoid arthritis
5%
Ras signaling pathway
5%
Melanoma
5%
Lysine degradation
5%
JAK-STAT signaling pathway
5%
Gap junction
5%
Epstein-Barr virus infection
5%
Protein digestion and absorption
10%
Prion diseases
10%
MicroRNAs in cancer
10%
Ferroptosis
10%
Axon guidance
10%
PI3K-Akt signaling pathway
15%
Human papillomavirus infection
15%
Focal adhesion
15%
ECM-receptor interaction
15%
Cell adhesion molecules (CAMs)
30%

(d)

Figure 4: Continued.
Figure 4: The protein-protein interaction (PPI) networks of common DEGs. (a–c) The comparisons of PPI networks of DEGs are shown among the indicated groups (group 1: healthy controls, group 2: inactive JSLE patients, and group 3: active JSLE patients) by using the STRING online database. The top 20 enrich KEGG pathways are selected and classified into hierarchical categories according to the comparison between groups.
The LDH release assay revealed that cell death was drastically increased in THP-1-derived macrophages in response to VTN stimulation (Figure 7(b)). These findings implied that VTN has a propyroptosis effect.

The results from the real-time PCR assay showed that VTN treatment led to a significant upregulation of IL-18 and GSDMD expression, a pivotal executioner of cell pyroptosis [27, 28], while no significant difference was obtained in IL-1β expression (Figure 7(c)). In line with this, the western blotting and quantified results also demonstrated that IL-18 and GSDMD expression was significantly enhanced in THP-1-derived macrophages treated by VTN stimulation compared with the control group (Figure 7(d)). Further results from ELISA suggested that IL-18 release was increased in response to VTN stimulation, and VTN has failed to alter IL-1β expression (Figure 7(e)). These findings suggested that VTN triggered GSDMD-executed cell pyroptosis, leading to the increase in IL-18 release to aggravate inflammation.

3.8. VTN Regulated Pyroptosis through Triggering NLRP3 Inflammasome Activation. The NLRP3 inflammasome, the well-known characterized inflammasome, consists of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1, which focused our attention to explore the effect of VTN on the NLRP3 inflammasome [29]. Based on this, we detected NLRP3 inflammasome changes in THP-1-derived macrophages with VTN stimulation. The results from qPCR and WB showed that VTN induced NLRP3 and caspase-1 expression in THP-1-derived macrophages, while no significant difference was obtained in ASC expression, leading to enhancing cleaved GSDMD and GSEMD-N expression (Figures 8(a) and 8(b)).

Our previous study has demonstrated that the NF-κB pathway is involved in cell pyroptosis [24], which further asked us to reveal the potential mechanism underlying VTN-regulated cell pyroptosis. As shown in Figure 8(c), phosphorylation of NF-κB was significantly increased in THP-1-derived macrophages in response to VTN treatment, while inhibition of NF-κB by BAY 11-7085 could reverse the induced effect of VTN on IL-18 expression and secretion (Figures 8(d)–8(f)). These findings suggested that VTN promoted cell pyroptosis through the NF-κB pathway.
The development of SLE is closely associated with the alteration in molecular functions, biological processes, and signaling pathways. However, the molecular characteristics and the molecular functions, pathways, and interactions in different stages of SLE are not well understood. In the currently study, we revealed 105 different proteins in the comparison between JSLE patients and healthy controls based on the proteomic assay. The results showed that these specific DEGs had different molecular functions, biological pathways, and formed complex interactome networks. What is more, we have found both urine EPHA4 and VTN levels are reduced in inactive and active JSLE patients when compared to healthy controls. Further bioinformatics analysis implied us that the EPHA4 and VTN in urine might have a potential possibility to be biomarkers of JSLE patients because of the clinical relationship between the pathological parameter and VTN. Most

4. Discussion

The development of SLE is closely associated with the alteration in molecular functions, biological processes, and signaling pathways. However, the molecular characteristics and the molecular functions, pathways, and interactions in different stages of SLE are not well understood. In the currently study, we revealed 105 different proteins in the comparison between JSLE patients and healthy controls based on the proteomic
Figure 7: VTN triggered cell pyroptosis. (a) LDH assay was performed to determine relative cell death in the indicated group in THP-1-derived macrophages; data represented the mean ± SD of three independent experiments; t-tests were used to analyze statistical significance; ***p < 0.001, **p < 0.01. (b) Real-time PCR was performed to examine the mRNA level of GSDMD, IL-1β, and IL-18 expression in THP-1-derived macrophages. Data represented the mean ± SD of three independent experiments; t-tests were used to analyze statistical significance; ***p < 0.001. (c) Western blotting was performed to test pyroptosis-related proteins, including GSDMD, IL-1β, and IL-18, in THP-1-derived macrophages with or without VTN (4 μM) stimulation, and the quantified results were analyzed by the t-test. Data represented the mean ± SD of three independent experiments; t-tests were used to analyze statistical significance; ***p < 0.001. (d) The contents of IL-1β and IL-18 in the supernatant and GSDMD/GSDMD-N expression of THP-1-derived macrophages with or without VTN treatment were detected by ELISA; data represented the mean ± SD of three independent experiments; t-tests were used to analyze statistical significance; ***p < 0.001, **p < 0.01. (e) IF assay was performed to detect GSDMD expression in THP-1-derived macrophages with or without VTN treatment.
Figure 8: VTN triggered the NF-κB pathway and NLRP3 inflammasome. (a) Real-time PCR and (b) western blotting were performed to detect ASC, NLRP3, and caspase-1 expression in THP-1-derived macrophages with or without VTN treatment. Data represented the mean ± SD of three independent experiments; t-tests were used to analyze statistical significance; *p < 0.05, **p < 0.01, and ***p < 0.001. (c) Phosphorylation of NF-κB was detected in THP-1-derived macrophages in response to VTN stimulation for 1 hour. (d, e) IL-18 was analyzed by western blotting and ELISA in THP-1-derived macrophages treated with VTN for 1 h, followed by BAY 11-7085 stimulation for another 48 hours. Data represented the mean ± SD of three independent experiments; one-ANOVA was used to analyze statistical significance; **p < 0.01, ***p < 0.001. (f) The schematic illustration for VTN-regulated cell pyroptosis.
importantly, VTN treatment led to a significant activation of NLRP3 inflammasomes, leading to cleaving GSDMD-N and IL-18 secretion to aggravate inflammation in THP-1-derived macrophages, suggesting that VTN might serve as a useful biomarker for clinical prognosis.

Coincidentally, it is reported that the high levels of VTN are associated with the circulating immune complex- (CIC-) soluble membrane attack complex (MAC) in SLE patients with active nephritis [30], implying the possible value of VTN in active nephritis. Interestingly, in our study, we further demonstrated a significant decreased level of urinary VTN and lower expression of serum C3 and C4 in inactive SLE and also a positive association between VTN and C3/C4, which may derive from the metabolic dissociation of CIC-MAC in JSLE glomerulus, identifying that a novel mechanism may contribute to the JSLE nephritis. What is more, it has been demonstrated that EPHA4 performed an important role in a number of cellular processes, including promoting cell proliferation and cell adhesion-mediated drug resistance via the Akt signaling pathway [30], while COL18A1 interacted with VTN and EPHA4 to modulate acute liver injury through binding αβ1 integrin on hepatocytes [31]. In addition, EPHA4 receptor-activation-mediated PI3K/Akt and Wnt/β-catenin signaling pathways as well as ERK1/2 play an important role in regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epithelial-mesenchymal transition development [32], which is in line with the analysis of these pathways as regulating epit...
KEGG: Kyoto Encyclopedia of Genes and Genomes
LC: Liquid chromatography
MAC: Membrane attack complex
MS: Mass spectrometry
NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells
NLRP3: Nod-like receptor family protein 3
PBMC: Peripheral blood mononuclear cell
PLT: Blood platelet
PPI: Protein-protein interaction
PRNP: Prion protein
S100: S100 calcium binding protein
uPAR: Urokinase plasminogen activator
VTN: Vitronectin
WBC: White blood cell.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval
The written informed consent was obtained from all subjects according to the Declaration of Helsinki. This protocol was approved by the Ethics Committee of Guangzhou Women and Children’s Medical Center.

Consent
Consent is not applicable.

Disclosure
The work has been presented as an e-poster in ICCR-2021 according to the following link: https://iccr2021.iccreg.com/e-poster/pdf/B-3-1.pdf, and the manuscript was submitted as a preprint in the following link: https://www.researchsquare.com/article/rs-103494/v1 [46].

Conflicts of Interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors’ Contributions
All authors made substantial contributions to study design, analysis, and interpretation of data, drafting the manuscript, and editing for important intellectual content of this article. Wanfu Xu, Zhe Cai, and Huasong Zeng were responsible for the study conception and design. Song Zhang, Zhe Cai, Wenxu Pan, and Xinhua Liang performed the experiments. Cheng Zhi, Yanhao Lin, Ping Wu, Qi Ren, Ping Wei, Rui Chen, Feng Li, Ying Xie, Song Zhang, and Hongli Wang were responsible for the acquisition of data. Chun Kwok Wong, Hong Tang, Wanfu Xu, and Huasong Zeng contributed reagents/materials/analysis tools. Wanfu Xu, Song Zhang, and Zhe Cai wrote the paper. Song Zhang, Wenxu Pan, and Hongli Wang contributed equally to this work.

Acknowledgments
We thank all authors’ contributions to this study. We thank the Department of Allergy, Immunology and Rheumatology for the kind support. This work was supported by the Guangdong Basic and Applied Basic Research Foundation (Nos. 2020A1515110109, 2021A1515012194, and 2020A1515110193), Guangzhou Municipal Science and Technology Project (No. 103270671136), Funding of Guangzhou Institute of Pediatrics/Guangzhou Women and Children’s Medical Center (No. GWCMC2020-1-005), Clinical Key Specialty and Construction of Cultivate the Key Subject of Guangzhou Women and Children’s Medical Center (No. 170000105), Guangzhou Medical Key Disciplines and Specialties (No. 011006003), National Health Commission Key Laboratory of Tropical Disease Prevention and Control (2022NHCITDCFKKT21001), Internal Funding of Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center Postdoctoral Fellow Research Project (No. 3001098), National Natural Science Foundation of China (No. 81873869), and Guangzhou 2018 Postdoctoral International Training Project.

References
[1] Q. Zhang, X. Yin, H. Wang et al., “Fecal metabolomics and potential biomarkers for systemic lupus erythematosus,” *Frontiers in Immunology*, vol. 10, p. 976, 2019.
[2] M. Barraclough, S. McKie, B. Parker et al., “Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes,” *Annals of the Rheumatic Diseases*, vol. 78, no. 7, pp. 934–940, 2019.
[3] T. Castro-Dopico and M. R. Clatworthy, “IgG and Fcgamma receptors in intestinal immunity and inflammation,” *Frontiers in Immunology*, vol. 10, p. 805, 2019.
[4] A. A. Herrada, N. Escobedo, M. Iruretagoyena et al., “Innate immune cells’ contribution to systemic lupus erythematosus,” *Frontiers in Immunology*, vol. 10, p. 772, 2019.
[5] W. Sui, X. Hou, W. Che, M. Yang, and Y. Dai, “The applied basic research of systemic lupus erythematosus based on the biological omics,” *Genes and Immunity*, vol. 14, no. 3, pp. 133–146, 2013.
[6] C. Arriens, J. D. Wren, M. E. Munroe, and C. Mohan, “Systemic lupus erythematosus biomarkers: the challenging quest,” *Rheumatology (Oxford)*, vol. 56, Supplement 1, pp. i32–i45, 2017.
[7] E. J. Lee, O. C. Kwon, B. Ghang et al., “Immunoglobulin binding protein 1 as a potential urine biomarker in patients with lupus nephritis,” *International Journal of Molecular Sciences*, vol. 20, no. 10, p. 2606, 2019.
[8] F. R. Spinelli, C. Garufi, S. Truglia et al., "The role of osteopontin as a candidate biomarker of renal involvement in systemic lupus erythematosus," *Clinical and Experimental Rheumatology*, vol. 37, no. 6, pp. 899–905, 2019.

[9] J. Lee, J. Lee, S. Baek et al., "Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome," *Journal of Autoimmunity*, vol. 100, pp. 114–119, 2019.

[10] C. M. Leu, T. S. Hsu, Y. P. Kuo et al., "Deftxl suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus," *Rheumatology (Oxford)*, vol. 58, no. 4, p. 740, 2019.

[11] D. J. Go, J. Y. Lee, M. J. Kang et al., "Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare," *Lupus*, vol. 27, no. 10, pp. 1600–1615, 2018.

[12] J. L. Turnier, N. Fall, S. Thornton et al., "Urine S100 proteins as potential biomarkers of lupus nephritis activity," *Arthritis Research & Therapy*, vol. 19, no. 1, p. 242, 2017.

[13] K. T. Preissner and D. Jenne, "Structure of vitronectin and its biological role in haemostasis," *Thrombosis and Haemostasis*, vol. 66, no. 1, pp. 123–132, 1991.

[14] J. Savill, I. Dransfield, N. Hogg, and C. Haslett, "Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis," *Nature*, vol. 343, no. 6254, pp. 170–173, 1990.

[15] Q. Huai, A. Zhou, L. Lin et al., "Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes," *Nature Structural & Molecular Biology*, vol. 15, no. 4, pp. 422–423, 2008.

[16] B. Singh, K. S. Janardhan, and R. Kanthan, "Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis," *Experimental Lung Research*, vol. 31, no. 8, pp. 771–782, 2005.

[17] J. M. Lopez-Guisa, A. C. Rassa, X. Cai, S. J. Collins, and A. A. Eddy, "Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease," *American Journal of Physiology. Renal Physiology*, vol. 300, no. 5, pp. F1244–F1254, 2011.

[18] J. W. Zmijewski, E. Lorne, X. Zhao et al., "Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 178, no. 2, pp. 168–179, 2008.

[19] J. Statland, C. M. Donlin-Smith, S. J. Tapscott, S. Van der Maarel, and R. Tawil, "Multiplex screen of serum biomarkers in facioscapulohumeral muscular dystrophy," *Journal of Neuromuscular Diseases*, vol. 1, no. 2, pp. 181–190, 2014.

[20] M. Harboe, J. Torvund-Jensen, K. Kjaer-Sorensen, and L. S. Laursen, "Ephrin-A1-EphA4 signaling negatively regulates myelination in the central nervous system," *Glia*, vol. 66, no. 5, pp. 934–950, 2018.

[21] M. T. De Angelis, G. Santamaria, E. I. Parrotta et al., "Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus," *Journal of Cellular and Molecular Medicine*, vol. 23, no. 11, pp. 7382–7394, 2019.

[22] D. D. Gladman, D. Ibanez, and M. B. Urowitz, "Systemic Lupus Erythematosus Disease Activity Index 2000," *The Journal of Rheumatology*, vol. 29, no. 2, pp. 288–291, 2002.

[23] C. S. Yee, V. Farewell, D. A. Isenberg et al., "British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 56, no. 12, pp. 4113–4119, 2007.

[24] Y. Wang, X. Zhou, K. Zou et al., "Monocarboxylate transporter 4 triggered cell pyroptosis to aggravate intestinal inflammation in inflammatory bowel disease," *Frontiers in Immunology*, vol. 12, article 644862, 2021.

[25] W. Xu, Z. Zhang, K. Zou et al., "MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis," *Cell Death & Disease*, vol. 8, no. 5, article e2761, 2017.

[26] L. Zhou, T. Liu, B. Huang et al., "Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development," *The Journal of Allergy and Clinical Immunology*, vol. 147, no. 1, pp. 267–279, 2021.

[27] L. Poh, S. W. Kang, S. H. Baik et al., "Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke," *Brain, Behavior, and Immunity*, vol. 75, pp. 34–47, 2019.

[28] D. Zhang, J. Qian, P. Zhang et al., "Gasdermin D serves as a key executioner of pyroptosis in experimental cerebral ischemia and reperfusion model both in vivo and in vitro," *Journal of Neuroscience Research*, vol. 97, no. 6, pp. 645–660, 2019.

[29] J. Xie, L. Fan, L. Xiong et al., "Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells," *BMC Pharmacology and Toxicology*, vol. 22, no. 1, p. 44, 2021.

[30] A. K. Chauhan and T. L. Moore, "Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC)," *Clinical and Experimental Immunology*, vol. 145, no. 3, pp. 398–406, 2006.

[31] M. B. Duncan, C. Yang, H. Tanjore et al., "Type XVIII collagen is essential for survival during acute liver injury in mice," *Disease Models & Mechanisms*, vol. 6, no. 4, pp. 942–951, 2013.

[32] P. G. de Marcondes and J. A. Morgado-Diaz, "The role of EphA4 signaling in radiation-induced EMT-like phenotype in colorectal cancer cells," *Journal of Cellular Biochemistry*, vol. 118, no. 3, pp. 442–445, 2017.

[33] K. Khodosevich, Y. Watanabe, and H. Monyer, "EphA4 preserves postnatal and adult neural stem cells in an undifferentiated state in vivo," *Journal of Cell Science*, vol. 124, no. 8, pp. 1268–1279, 2011.

[34] C. P. Chung, M. J. Ormseth, M. A. Connelly et al., "GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus," *Lupus*, vol. 25, no. 3, pp. 296–300, 2016.

[35] F. Nordin, S. S. Shaharir, A. Abdul Wahab et al., "Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus," *International Journal of Rheumatic Diseases*, vol. 22, no. 8, pp. 1419–1426, 2019.

[36] H. Idborg, A. Zandian, E. Oissipova et al., "Circulating levels of interferon regulatory factor-5 associates with subgroups of systemic lupus erythematosus patients," *Frontiers in Immunology*, vol. 10, p. 1029, 2019.

[37] K. M. Munro, K. J. Dixon, M. M. Gresle et al., "EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE)," *PLoS One*, vol. 8, no. 2, article e55948, 2013.

[38] M. Pazhouhandeh, M. A. Sahraian, S. D. Siadat et al., "A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients," *Clinical and Experimental Immunology*, vol. 192, no. 1, pp. 18–32, 2018.

[39] Z. Cai, C. K. Wong, N. W. Kam et al., "Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus," *Lupus*, vol. 24, no. 12, pp. 1257–1266, 2015.
References

[40] B. Sumova, L. A. Cerezo, L. Szczukova et al., “Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study,” *Rheumatology International*, vol. 39, no. 3, pp. 469–478, 2019.

[41] S. Ajmani, H. Singh, S. Chaturvedi et al., "Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis,” *Clinical Rheumatology*, vol. 38, no. 4, pp. 997–1005, 2019.

[42] M. P. Keasey, C. Jia, L. F. Pimentel, R. R. Sante, C. Lovins, and T. Hagg, "Blood vitronectin is a major activator of LIF and IL-6 in the brain through integrin-FAK and uPAR signaling," *Journal of Cell Science*, vol. 131, no. 3, 2017.

[43] C. Jia, M. P. Keasey, H. M. Malone et al., "Vitronectin from brain pericytes promotes adult forebrain neurogenesis by stimulating CNTF," *Experimental Neurology*, vol. 312, pp. 20–32, 2019.

[44] H. Tochimaru, K. Yasuda, Y. Takekoshi, and S. Mastumoto, "Current topics in childhood lupus nephritis," *Acta Paediatrica Japonica*, vol. 35, no. 5, pp. 480–487, 1993.

[45] Y. S. Yi, "Role of inflammasomes in inflammatory autoimmune rheumatic diseases," *The Korean Journal of Physiology & Pharmacology*, vol. 22, no. 1, pp. 1–15, 2018.

[46] S. Zhang, C. A. I. Zhe, C. Zhi et al., "Proteomic analysis for identification of novel urinary biomarkers in juvenile systemic lupus erythematosus," 2020, https://www.researchsquare.com/article/rs-103494/v1.